This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Moore, Kathleen
| Item Type | Name |
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Recurrence
|
|
Academic Article
|
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
|
|
Academic Article
|
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
|
|
Academic Article
|
Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?
|
|
Academic Article
|
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
|
|
Academic Article
|
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
|
|
Academic Article
|
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
|
|
Academic Article
|
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
|
|
Academic Article
|
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
|
|
Academic Article
|
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
|
|
Academic Article
|
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
|
|
Academic Article
|
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
|
|
Academic Article
|
Patterns and utility of routine surveillance in high grade endometrial cancer.
|
|
Academic Article
|
Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer.
|